Liver failure is one of the main causes of death worldwide and is a growing health problem. Since the discovery of stem cell populations capable of differentiating into specialized cell types, including hepatocytes, the possibility of their utilization in the regeneration of the damaged liver has been a focus of intense investigation. A variety of cell types were tested both in vitro and in vivo, but the definition of a more suitable cell preparation for therapeutic use in each type of liver lesions is yet to be determined. Here we review the protocols described for differentiation of stem cells into hepatocytes, the results of cell therapy in animal models of liver diseases, as well as the available data of the clinical trials in patients with advanced chronic liver disease.
INTRODUCTION
N-2 acetylaminofluorene (AAF) (141) and also in livers of mice following administration of retrorsine and partial hepatectomy (65). The presence of oval cells in in-The liver is the target of a number of diseases of acute or chronic courses. Diverse types of hepatic injur-jured livers has also been identified in patients (8). Initially, it was described that oval cells arise from the bile ies caused by toxic, metabolic, infectious, or traumatic agents lead to series of precisely regulated physiologic ducts or canals of Hering (128) . More recently, the observation that oval cells share some markers with hema-events called liver regeneration (32). The hepatocyte is a highly differentiated epithelial cell that maintains the topoietic cells, such as CD34, Thy-1, and Sca-1, has led to the hypothesis that oval cells can arise from bone potential of division, being able to enter the cell cycle whenever is necessary. Therefore, liver regeneration is marrow, but the available data are still conflicting (19, 95, 132) . A recent work showed that bone marrow primarily based on the compensatory hyperplasia of the remaining parenchyma that occurs until the original he-cells can fuse with oval cells (59). Thus, although their existence and bipotential nature are well established, the patic mass is recovered (62, 87) .
When the injury process causes impairment in hepa-origin of oval cells remains uncertain. Nonetheless, their important role in hepatic regeneration makes them a pu-tocyte division, however, regeneration can still occur through the activation and differentiation of intrahepatic tative cell population for therapeutic use in liver diseases. progenitors called oval cells (86). These cells can differentiate into either hepatocytes or cholangiocytes and can In addition to oval cells, another cell population known as small hepatocyte-like progenitors was described be easily identified in livers of rats submitted to hepatic injury with carbon tetrachloride (CCl 4 ) associated with in rats following hepatectomy and administration of ret-rorsine. This cell population is phenotypically distinct are not innocuous, and the procedure-associated risks are increased in patients with chronic liver diseases. Fur-from differentiated hepatocytes, cholangiocytes, and oval cells (39, 40) . There is still controversy whether these thermore, bone marrow hypoplasia-frequently found in patients with advanced liver diseases-may limit the cells represent an intermediate state in oval cell differentiation or are derived from hepatocytes resistant to retro-number of isolated stem cells. In terms of expanding the cells in vitro, longer time spent and higher costs are still rsine treatment (10,131).
According to the described data, hepatic regeneration limiting. There is also concern on the possibility of chromosome alterations, which could be induced by long-can occur through three different cell lines: hepatocytes, intrahepatic stem cells, or extrahepatic stem cells (110) .
term cell culture, and risk of malignancies after transplantation (18) . Therefore, assessing the real benefits Despite the regenerative potential of the liver, chronic and persistent hepatic injuries lead to a sustained wound-that stem cell therapy may provide to patients with chronic liver diseases will be necessary in order to estab-healing response and the development of fibrosis. In advanced diseases a distortion of the parenchyma with for-lish a cost-effectiveness analysis. In the following sections we reviewed available data on in vitro, preclinical, mation of hepatocellular nodules and fibrous septae characterizes liver cirrhosis. Studies have shown that, and clinical studies on stem cell therapy and liver diseases. even in patients with chronic liver diseases, fibrosis can be reversible when the aggression to the organ is con-STEM CELLS: CONCEPTS AND DEFINITIONS trolled (13).
Liver transplantation is still the only option for pa-There are two types of stem cells that can be employed in the regeneration of a damaged liver: embry-tients with end-stage hepatic disease and has limitations like the scarcity of donors, high costs, possibility of re-onic stem cells (ESCs) and adult stem cells. ESCs are derived from the inner cell mass of blastocyst stage em-jection, and necessity for immunosuppression.
Hepatocyte transplantation has been investigated as bryos (70, 82) and adult stem cells, like mesenchymal stem cells (MSCs), that can be isolated from postnatal an alternative treatment for several liver diseases. The use of hepatocye infusions was first tested in an experi-tissues, expanded in vitro as adhesion-derived cells, and induced to differentiate into multiple cell types (7). mental model for Crigler-Najjar syndrome (72). Over the years many studies with animal models were used Stem cells can be classified as totipotent, pluripotent, or multipotent. A multipotent cell can give rise to multi-for correction of acute liver failure, inborn errors of metabolism (43, 74, 134) , and to improve liver function of ple cell types not restricted to a single germ layer. A pluripotent cell should be able to give rise to all cell rats with decompensated cirrhosis (58).
The good results obtained in experimental studies types that are found in an adult organism. A totipotent cell is a cell that can produce an entire organism, includ-with hepatocyte transplantation in models of hepatic injury allowed the proposition of clinical trials in patients ing extraembryonic membranes and placenta. Nowadays, confusion seems to occur with this classification with liver diseases. These studies demonstrated the recovery of hepatic encephalopathy in patients with acute and there is no consensus on the precise meaning of those terms. Although it is possible to derive an entire hepatic failure (11,44,56), but only in 2 of the 10 cirrhotic patients evaluated (76) . mouse from an ESC, some authors (114) classify ESCs as pluripotent because a tetraploid embryo would be re-For treatment of liver-based metabolic diseases, hepatocyte transplantation was more successful, as demon-quired to form the extraembryonic membranes and placenta (83) . Other authors, however, classify ESCs as to-strated in studies with patients with Crigler-Najar syndrome type I, glycogen storage disease, and ornithine tipotent, MSCs as pluripotent, hepatoblast cells as multipotent, and hepatocyte as specialized cells (21) . transcarbamylase deficiency, among others (35, 48, 81) . However, the clinical trials carried out had few patients
The development of protocols to induce stem cells to undergo a hepatic-commitment pathway and to finally included and needed more accurate studies. Moreover, the correction of metabolic defects was transient, sug-give rise to functional mature hepatocytes for transplantation is a matter of great interest. Currently, hepatocyte gesting a progressive loss of transplanted cells (34, 111) . In this setting, stem cells transplantation is of great inter-transplantation is still limited by the available supply of liver donors (25) and their rapid elimination by recipient est as an alternate and promising therapeutic approach. At this point, however, there is still much to be clarified macrophages (38) . Being an allogeneic transplant, the fate of transplanted hepatocytes needs investigation (99) . and some challenges persist. Whether stem cells can help repair injured livers, by which mechanisms, and Furthermore, specialized cell types, such as mature hepatocytes, cannot be expanded in vitro and techniques what would be the ideal cell source are only some of the questions that need to be answered. Also, the protocols to proliferate hepatocyte progenitor cells basically depend on liver donations (109) . This could be easily over-involved with stem cell extraction and transplantation come by using stem cell cultures, especially ESCs, onic hepatic development happens due to a sequence of events that start during the gastrula phase of embryogen-which are highly proliferative. However, ESCs cells have a high neoplastic potential ( Fig. 1 ) and therefore esis when the endoderm is initially segregated from the ectododerm and mesoderm. This segregation exposes attention must be paid for the possibility of teratoma development (75) . This obstacle makes MSCs a suitable the endoderm to several domains with distinct differentiation potential. The domain with hepatic competence type of stem cells for hepatocyte differentiation due to their good proliferative potential, high plasticity (7), and initiates the primary hepatic induction after receiving signs from cardiac mesoderm and septum transversum considerable less neoplastic potential compared to ESC (21) . Although MSCs represent a promising source, the mesenchyme. The response to those signs is the beginning of the primary hepatic program. In sequence, dur-achievement of means to overcome technical issues concerning isolation from a given tissue, expansion, differ-ing the secondary hepatic induction, the immature liver invades the septum transversum. This invasion leads to entiation into hepatocyte-like cells procedure, and, especially, making this process an economically viable a period of intense growing and differentiation originating a mature and functional organ. The genes that con-alternative still remains a challenge. trol those events, as well as the signs responsible for MOLECULAR MECHANISMS INVOLVED IN coordinating the liver formation during embryogenesis,
THE EARLY DEVELOPMENT OF THE LIVER
have been extensively reviewed (22, 28, 73, 116, 143, 144) . ESCs and MSCs can be directed to differentiate to-Progenitor cells have the ability to differentiate (i.e., to acquire new morphology and functional characteris-wards a cell lineage in certain culture conditions. Specific drugs and growth factors that induce cell prolifera-tic) (126) . The derivation of a large number of functional hepatocytes from stem cells remains a challenge. tion and differentiation during the development of an organism can be added to the medium in a stem cell A better understanding of the molecular mechanisms that control hepatogenesis led to the development of culture. The mechanisms that control hepatogenesis are not fully understood, although important discoveries in strategies for directing the hepatic differentiation of stem cells in vitro. Recent advances in molecular genetics, this area allowed the proposition of many protocols aiming to direct the differentiation of MSCs (55,113,122) molecular biology, and embryology made possible the identification of a series of signs generated during the and ESCs (2) into hepatocyte-like cells. Studies involving the signaling from cardiac meso-development of an embryo. It is now known that embry- derm towards differentiation of hepatic progenitors of represents a specific class I and II histone deacetylase (HDAC) inhibitor (142) . HDAC regulates gene expres-endodermic intestinal revealed that a group of molecules identified as fibroblast growth factors (FGF) was re-sion (61) and it was proposed that TSA, accompanied by hepatogenic agents, would select the survival of dif-sponsible for directing cell migration and hepatic differentiation (52) . Other reports confirmed that FGF-4 in-ferentiating cells towards the hepatocyte lineage by inducing apoptosis of nonhepatic differentiating cells (112). ducts differentiation of MSC isolated from bone marrow (55, 112) and other tissues (54) into hepatocyte-like cells.
Elucidation of interactions between chemical substances and specific factors linked to hepatic develop-The class of hepatocyte nuclear factor (HNF) proteins and their target genes were studied in embryoid bodies ment may allow, in the near future, the obtention of in vitro hepatocytes differentiated from stem cells. obtained from ESC. HNF3 factors are involved on nucleossomal organization of albumin gene as well as regula-HEPATOCYTE-LIKE CELLS tion of HNF4 promoter (member of receptor family of steroids hormones). HNF4-α is essential for morpholog-Several studies reporting the generation of hepatocyte like-cells from adult derived human liver mesenchymal-ical and functional differentiation of hepatocytes (94) . In normal embryos, during the developing endoderm, like cells (84) as well as from different stem cell types of extrahepatic human tissues have been published (Ta-HNF3-β is expressed before HNF3-α, being this sequence necessary for the expression of HNF3-α. The ble 1). It is not certain whether any of these can function as mature hepatocytes with potential to be used for the expression of both factors simultaneously results in an antagonist effect, decreasing the transcriptional capacity treatment of liver diseases. Although it is a considerable step towards successful differentiation, knowledge con-of HNF3-β. The presence of insulin increases the expression of the regulator HNF3-β and decreases HNF3-cerning liver organogenesis and also biology of stem cells has yet to define some crucial steps in order to α, leading to a higher expression of HNF4 as well as other liver-specific genes whose products are important achieve a feasible protocol to differentiate a stem cell into functional and transplantable hepatocytes. to glucose metabolism (29). Insulin is used in protocols to differentiate MSC into hepatocyte-like cells (112).
The development of adequate culture conditions, dosage and combination of cytokines and growth factors, as The fact that insulin and other agents act in a coordinated way suggests that those factors should be added well as their sequence exposure is crucial for directing the hepatic differentiation of stem cells in vitro. A good sequentially and respecting a specific timing (113) .
Dexametasone is a synthetic corticosteroid used as example would be the study of Snykers and colleagues: when hepatogenic factors were added in a sequential supplement in primary hepatocyte culture. This chemical compound induces the expression of hepatocyte differ-manner, reflecting their temporal expression during in vivo hepatogenesis, instead of a cocktail kind of expo-entiated phenotype by suppressing cell division (45) .
While many signs are involved in differentiation, oth-sure, the cells presented enhanced hepatic differentiation (112). ers control the growth of the developing liver. Some pathways that control proliferation of the fetal liver in-
The source of stem cells is an important issue concerning transplantable hepatocyte-like cells. Autologous volve hepatocyte growth factor (HGF). Beyond a potent mitogen, HGF influences cell migration and motility transplantation would be more preferable than allogeneic or embryonic once it eliminates the risk of rejection through transmembrane signals of tyrosine kinase by activation of its receptor, cMet. There is evidence that the and represents a feasible source of cells with no ethical implications. ESC pluripotency and unlimited self-path HGF/cMet is responsible for the interaction between mesenchymal and epithelial cells during develop-renewal capacity (82) corroborate with reports showing their potential in generating hepatocyte-like cells (2). ment. While HGF is expressed in mesenchymal cells, cMet is expressed in epithelial cells near the organs un-However, it seems that the successful use of a given cell source will depend on future research and the overcome der development (28).
Oncostatin M (OSM) is a member of the interleukin-of technical challenges. An adult hepatocyte phenotype was not reached using 6 cytokine family and seems to coordinate liver development and hematopoiesis in the fetus (77). The inclusion human adipose tissue-derived cells (122). In another study, after differentiation of human adipose tissue stem of nicotinamide, dimethyl sulfoxide (DMSO), and OSM in the culture medium was shown to have an important cells into hepatocyte-like cells, it was examined whether the generated hepatocytes were therapeutically applica-role in the development and differentiation of hepatocytes by enhancing in vitro maturation of fetal mouse ble by transplantation into CCl 4 -injured mouse. The hepatocytes were incorporated into host livers and in those liver cells when compared with conventional culture conditions (105) . mice some liver functions were improved, indicating that they might be applicable for transplantation (8). Trichostatin A (TSA) is a fungistatic antibiotic and cells with hepatocyte tocyte-like functions: ture medium supple-sequential exposure. morphology express-ability to store glycomented with KOSR ing a repertoire of gen, uptake and reand Activin A.
characteristic genes lease indocyanine and hepatocyte-spe-green (ICG), and albucific markers analyzed min secretion. by immunofluorescence and RT-PCR.
Adipose tissue Culture of adherent HGF, bFGF, Morphology and de-Not performed. 122 passage 2 cells at 85% ITS+premix, OSM, tection of hepatocyteconfluency in serum-nicotinamide, dexa-specific markers by deprived medium sup-methasone; two step RT-PCR and immunoplemented with EGF protocol. histochemistry showed and bFGF were used expression of albumin for differentiation and CYP isozymes. assay.
Hepatogenic differentiation was successful, although the hepatocyte adult phenotype was not reached.
Passage 2 cultures of FGF1, FGF4, HGF, RT-PCR, immuno-The analysis of glyco-8 adherent cells in cul-OSM, dexametha-staining, and Western gen storage, albumin ture medium supple-sone; sequential expo-Blot detection of hepa-secretion, and ammoment with FBS fol-sure. tocyte-specific mark-nia clearance from cullowed by isolation of ers. ture media revealed the CD105 positive.
60-85% functional and transplantable hepatocytes.
Monocytes
Adherent cells were FGF-4; two-step pro-Cells presented hepa-In vitro metabolic 103 cultured for 6 days in tocol.
tocyte-like morpho-functions (albumin seculture medium sup-logic characteristics cretion, urea producplemented with human and expression of tion, lactate formation, serum, β-mercaptoethliver specific proteins. lactate dehydrogeanol, macrophage col-nase, and aspartate ony stimulating factor, transaminase release) and human interleu-were shown to be in kin-3. part comparable with those of primary human hepatocytes.
Bone marrow
Culture of adherent HGF, bFGF, Morphology and detec-Not performed. 122 passage 2 cells at 85% ITS+premix, OSM, tion of hepatocyte-speconfluency in serum-nicotinamide, dexa-cific markers revealed deprived medium sup-methasone; sequential expression of albumin plemented with EGF exposure. and CYP isozymes. and bFGF were used Hepatogenic differenfor differentiation tiation was successful, assay.
although the hepatocyte adult phenotype was not reached.
(continued) Fourth passage culture FGF-4, HGF, ITS, Cocktail: Acquisition Albumin secretion, 112 of adherent cells at dexamethasone, TSA of an epithelial mor-urea production, and 100% confluency was (on the 6th day of ex-phology and immuno-CYP-dependent activused for differentia-posure); cocktail and fluorescence for hepa-ity assay and acquired tion assay. sequential exposure. tocyte-specific functional maturation. markers was performed. Cells expressed hepatocyte markers comparable to their expression pattern during in vivo hepatogenesis. Sequential exposure:
Albumin secretion, A homogeneous popu-urea production, and lation of epithelioid CYP-dependent activcells was obtained and ity assay and acquired immunofluorescence functional maturation for hepatocyte-specific more prominent than markers was per-the cells under cockformed. About 70% of tail exposure. cells expressed hepatocyte markers comparable to their expression pattern during in vivo hepatogenesis.
Adult stem cells represent a heterogeneous popula-
PRECLINICAL STUDIES tion (7), and therefore only a small proportion of cells are capable of differentiation into hepatocyte-like cells.
The majority of the experimental work published at this moment has focused on the transplantation of stem It was observed that a small percentage of cells after differentiation express characteristic liver markers such cells without hepatocyte differentiation protocols. Most studies have also performed cell transplantation by intra-as albumin, transferring, and HNF3-β. In addition, those cells have much lower enzymatic competence when venous systemic infusions. The first parameter to be analyzed is whether stem cells can migrate to the targeted compared to primary hepatocyte culture (45) . To avoid heterogeneity of cells, an isolation step can be added tissue or organ. A recent work showed that, in noninjured rats, the majority of the cells intravenously infused before the differentiation procedure, such as selection of CD105-positive cells (8).
were trapped inside the lungs and only small numbers actually reached the arterial system acutely (33). Despite Peripheral blood would be an interesting readily accessible source of cells for generation of hepatocyte-like this observation, several studies with different experimental models of hepatic diseases have demonstrated cells. It was reported that human peripheral blood monocytes can differentiate into hepatocyte-like cells (146) that, even when systemically infused, stem cells can migrate, engraft, and promote functional recovery of the with some in vitro metabolic functions comparable to those of primary human hepatocytes (103) . liver after cell therapy (Table 2) . This was found in mice knockout for fumarylacet-Although many sources of cells have been investigated, the question of whether these are the best sources oacetate hydrolase (Fah) after the transplantation of bone marrow cells, with a reduction in levels of trans-of stem cells for cell therapy in patients with liver diseases remains unclear.
aminases and bilirubin (63,130), as well as in mice with CCl 4 -induced hepatic injury, which showed a rise in se-is a safe procedure with extensive clinical experience. The protocols used do not involve cell culture and there-rum albumin and decreased prothrombin time (51, 91) , and in a model of injury by partial hepatectomy and fore may be simpler and less expensive. However, transplanted cells in these cases do not represent a single dietylnitrosamine (DEN), showing a reduction in aspartate transaminase (AST), alanine transaminase (ALT), purified lineage of cells, being a heterogenous cell population in which stem cells represent only a small frac-hyaluronic acid, and laminin (147) . A rise in the production of albumin was also demonstrated by our group tion. The relationship between liver and bone marrow be-after therapy with bone marrow cells in a mice model of chronic infection by Schistosoma mansoni (89) .
gins in the fetal liver, a major site of hematopoiesis (92). Furthermore, there is evidence that the inverse process The mechanisms underlying the therapeutic effects of stem cells transplantation in liver diseases could involve can occur in the adult liver. Hepatocytes carrying Y chromosome were detected in livers of female recipients transdifferentiation, cell fusion, or paracrine bystander actions (Fig. 2 ). It has been suggested that the presence, of bone marrow transplantation from male donors (127) . Therefore, investigating the therapeutic potential of bone severity, and type of hepatic injury could be important in regulating the plasticity of stem cells (71) . With the marrow cells has been a matter of studies with several experimental models of hepatic diseases. increasingly data available, transdifferentiation is now known to not occur, or only in very small frequency, Lagasse and colleagues worked with the experimental model of type I tyrosinemia, in which mice are deficient leading the therapeutic effects to paracrine actions or cell fusion. In the following sections, we detail the main for Fah, a crucial enzyme in the final steps of tyrosine metabolism, and therefore this is associated with in-findings with stem cell therapies using different cell types, such as bone marrow cells, mesenchymal stem creased hepatocyte death (63). Authors demonstrated that the intravenous infusion of bone marrow cells from cells, cord blood cells, and intrahepatic progenitors, as well as therapy with growth factors in experimental wild-type donors increased survival rates through the correction of the metabolic disorder. Transplanted bone models of liver diseases. marrow cells gave rise to nodules of hepatocytes Fah +/+ , Bone Marrow Cells repopulating the liver with bone marrow-derived hepatic cells. In this model, donor-derived hepatocytes ac-Autologous transplantation of bone marrow cells is as an interesting option in regenerative medicine because it counted up to 30% of the total liver cells. This high level of repopulation was achieved because of the high duction in fibrosis percentage and enhanced survival rates in mice treated with intravenously injection of selective pressure favoring the transplanted cells found in this model. These results were confirmed by Vassilo-bone marrow cells after CCl 4 -induced acute injury. The authors suggested that transdifferentation into hepato-poulos et al. (130) and Wang et al. (133) . In these two studies, authors concluded that the main mechanism in-cytes had occurred (107). Fibrosis reduction was reported in rats with CCl 4 -induced liver fibrosis after bone volved in the generation of bone marrow-derived hepatocytes was cell fusion. Similar results were found in marrow mononuclear cells transplantation (15) . A reduction in liver fibrosis was also demonstrated in the experi-mice transplanted with purified myelomonocytic cells and bone marrow-derived macrophages (14, 136) . mental model of hepatectomy and dimetylnitrosamine administration (145, 147) and in hepatic fibrosis caused The contribution of bone marrow cells in reducing liver fibrosis has also been investigated with positive by chronic infection by Schistosoma mansoni (89) . The correlation of fibrosis reduction and lower levels results achieved in the majority of the studies; however, high levels of liver repopulation by transplanted cells of TGF-β, a cytokine that plays a key role in fibrogenesis, was also demonstrated after cell therapy (31,89). were not demonstrated. An extensively studied experimental model is CCl 4 -induced liver fibrosis. In this Corroborating those findings, levels of matrix metalloproteinases, which are enzymes responsible for matrix model, fibrogenesis occurs in a dose-dependent and time-dependent manner in rats and mice (123) . Jang and degradation, were found to be elevated following therapy in some studies (98, 106, 107) . Increased expression colleagues demonstrated that a population of bone marrow purified stem cells can transdifferentiate into hepa-of matrix metalloproteinases was also reported in bone marrow-derived cells found in livers of chimeras during tocytes in vitro and in vivo, contrary to the results found in Fah −/− mice (51) . Transplantation of bone marrow the fibrosis resolution phase (46) . Our group studied the model of hepatic cirrhosis in-cells also promoted a functional improvement in mice with acute injury caused by CCl 4 . Sakaida and col-duced in mice by chronic administration of CCl 4 associated with ethanol and the model of periportal fibrosis leagues observed improvement in hepatic function, re-induced by chronic infection by Schistosoma mansoni.
is possible that the contribution of different mechanisms, like cell fusion and paracrine effects may occur depend-The presence of hepatocytes of donor origin in the liver was detected 2 months after the treatment. It was ob-ing on the cell populations transplanted and also on the type of injury occurring in the liver. served that the infusion of bone marrow mononuclear cells promoted a reduction in fibrosis and improved al-Mesenchymal Stem Cells bumin production (89) . Dahlke reported that the infusion of bone marrow cells did not result in a functional bene-A small fraction of the bone marrow stromal cells called mesenchymal stem cells have been a matter of fit in terms of survival rates in the experimental model of acute hepatic failure induced by retrorsine and CCl 4 study in regenerative medicine. Their pluripotency and therapeutic effects have been well described in different (20) .
The ability of bone marrow cells to give rise to he-models of degenerative diseases (16) . These cells physiologically give support to hematopoiesis by cell contact patic nonparenchymatous cells involved in the modulation of liver fibrosis has been reported with conflicting and secretion of a number of cytokines and growth factors (23) . They are characterized by being plate adher-conclusions. Duffield demonstrated that bone marrowderived macrophages played an important role in the ent, capable of self-renewing, negative for hematopoietic cell markers and having potential of differentiation resolution of fibrosis caused by CCl 4 (27) . This seems to occur through an increased production of MMP-13 into mesenchymal lineages. Besides bone marrow, a variety of tissues have been used as sources of mesenchy-(30). On the other hand, some recent studies have pointed to a profibrogenic potential of bone marrow mal stem cells, like adipose tissue, umbilical cord blood, and dental pulp (42,54,119). It has been shown that cul-cells transplantation, because it has been demonstrated that hematopoietic stem cells have the ability to differ-tured mesenchymal stem cells can differentiate into a hepatocyte phenotype under appropriate conditions, in-entiate into stellate cells after transplantation (78) . Hepatic stellate cells play a key role in liver fibrogenesis, dicating the potential use of these cells in hepatic diseases (90). In addition to their pluripotency, mesenchymal due to its ability in differentiating into myofibroblasts and secrete components of extracelular matrix. Other stem cells have been shown to have immunomodulatory properties and to be able to secrete a number of factors studies reported the presence of myofibroblasts derived from bone marrow contributing for fibrogenesis (57, involved in tissue regeneration and reduction of inflammation (23, 101) . Mesenchymal stem cells can also be 104). Asawa and colleagues also showed the potential of bone marrow cells in converting into cells with a fi-regulated by other cells. Recent studies demonstrated that mesenchymal stem cells cocultured with hepatic broblast and myofibroblast phenotype in an early phase of periductular fibrosis (6). These results came from stellate cells had enhanced proliferation and differentiation into hepatocyte-like cells (24, 66) . studies with bone marrow chimeras and the relevance of those findings in the scope of the possible alterations It has been shown that mesenchymal stem cells can migrate and engraft into injured liver. The administra-seen after transplantation has yet to be clarified.
Because the participation of progenitor cells is physi-tion of mesenchymal stem cells marked with iron particles in the portal vein of rats with hepatic injury induced ologically required when hepatocyte proliferation is blocked or in the setting of extensive injuries, stem cell by administration of CCl 4 allowed the demonstration, through magnetic resonance analysis, that these cells re-transplantation is also a promise in the treatment of massive hepatic necrosis. This was evaluated in the experi-mained in the liver up to 12 days after the injection (12). The therapeutic potential of bone marrow mesenchymal mental model of acute liver failure induced by acetaminophen in rats. In this study, bone marrow mononuclear stem cells was first tested in a model of acute liver injury in mice treated with CCl 4 (31). The syngeneic trans-cells injection into the portal vein 24 h after the drug administration promoted a significant reduction in mor-plantation of mesenchymal stem cells immediately after the administration of CCl 4 reduced the hepatic damage, tality and in liver necrosis. However, liver repopulation by donor cells was not evaluated in this study (9). the development of fibrosis, and accelerated liver regeneration. It was observed a correlation between the reduc-Most of the studies described above point out for a therapeutic effect of bone marrow cell transplantation in tion of collagen and the levels of TGF-β in the animals treated with mesenchymal stem cells immediately after hepatic diseases. However, which cell populations would be responsible for the reported effects and the the administration of CCl 4 . Hepatic cells with Y chromosome were found in the liver of the female mice trans-precise mechanisms involved are still matter of discussion. The results found may be diverse due to the partic-planted with mesenchymal cells of male donors. These cells appeared in small numbers, showing low levels of ularities and differences between the experimental models studied or the methods used in the investigations. It repopulation. Although in this model positive results were found when the cells were injected immediately Umbilical Cord Blood Cells after the injury induction, it was not observed any benefit when the cells were injected 1 week later.
The umbilical cord blood is a source of young hematopoietic and mesenchymal stem cells that therefore Bone marrow mesenchymal stem cell transplantation was also beneficial in models of hepatic fibrosis in rats could have advantages in plasticity upon other types of adult stem cells for regenerative medicine. A major (1,145). Zhao and colleagues induced liver fibrosis by administration of either CCl 4 or dimetylnitrosamine problem for clinical use is that availability of these cells for autologous transplants requires the presence of a (DMN) and the animals were injected with bone marrow mesenchymal cells intravenously at different time points cord blood banking. In case of heterologous transplants, rejection could occur and immunossupression could be (145) . The authors observed a reduction in mortality, weight, collagen deposition, and an improvement in bio-needed. However, it has been shown that cord blood contains cells with the potential of differentiation in he-chemical parameters of liver function. The sooner the transplantation occurred, the better were the therapeutic patocytes in vitro, indicating a possible use in the treatment of liver diseases (47, 53) . Kang and colleagues also effects found. In another study, mesenchymal stem cells injected into the portal vein were able to differentiate demonstrated in vitro differentiation of cord blood mesenchymal stem cells cultured in the presence of fibro-into hepatocytes, reduce fibrosis, and restore hepatic function (147) .
blast growth factor-4 (FGF-4) and HGF (54) . The experimental work with cord blood cells has In opposition to the results described above, a recent study by Carvalho and colleagues demonstrated that been based upon the xenotransplantation of human cells into mice or rats, usually of immunodeficient lineages. mesenchymal stem cells injection into the portal vein of rats with liver cirrhosis induced by CCl 4 and ethanol did Di Campli and colleagues investigated the therapeutic potential of human cord blood cells in a murine model not reduce hepatic fibrosis or promote any improvement in parameters of liver function (17). Oyagi and col-of hepatic injury caused by administration of allyl alcohol to immunodeficient NOD/SCID mice. The cord leagues also failed to demonstrate benefits in transplantation of mesenchymal stem cells in rats with CCl 4 -blood mononuclear cells were injected intraperitoneally after induction of hepatic injury (26) . The authors ob-induced liver fibrosis (91) . However, the authors pointed out that transplantation of mesenchymal stem cells cul-served that the transplanted cells differentiated into hepatocytes and promoted an improvement in liver func-tured in the presence of the hepatocyte growth factor (HGF) was beneficial, promoting a significant improve-tion and in survival rates. Similar results were obtained by Tang and colleagues, in a model of acute liver failure ment in serum albumin and transaminases, and also a reduction in fibrosis (91) .
induced by carbon tetrachloride in rats. In this study, the animals that received cord blood cells intraperitoneally Most of the studies with mesenchymal stem cells showed a poor liver repopulation, although most were 3 days after the administration of CCl 4 had a significant improvement in liver function and survival rates (124) . associated with benefic results. This was also seen in an experimental model of acute liver failure (60). The Histological analysis of the liver after 5 days demonstrated reduced numbers of inflammatory cells and ne-possibility of occurrence of paracrine action was evaluated in a recent work with the experimental model of crosis area. Functional donor-derived hepatocytes expressing albumin mRNA were found in sublethally acute liver failure induced by D-galactosamine in rats. After hepatic injury induction, rats that received mesen-irradiated NOD/SCID mice transplanted with human cord blood cells (50, 83) . Furthermore, Piscaglia and col-chymal stem cell-conditioned medium intravenously had reduced mortality levels. This was associated with a leagues demonstrated that the infusion of cord blood cells in rats with liver injury caused by administration of 90% reduction in hepatocytes apoptosis and a threefold increase in proliferation of hepatocytes, suggesting that allyl alcohol improved liver regeneration. By microarray analysis, the authors demonstrated that cell therapy pro-the therapy had enhanced liver endogenous regeneration programs (129) .
moted an enhancement in the expression of 256 genes and a reduction in 149 genes. The upregulated genes The beneficial results found in the majority of the experimental studies with mesenchymal stem cells in included those involved in cell proliferation, differentiation, adhesion, cell migration, and oval cell activation liver diseases encourage clinical studies. However, there is still concern in respect to genetic and chromosomic (98) . In an experimental model of hepatitis induced by D-galactosamine, improvement in histological damage alterations that could be found in cultured and expanded cells (102) and therefore cytogenetic control is needed and liver function reduction was observed when human umbilical cord blood mononuclear cells were intrapor-for discharging the risk for neoplastic transformation before clinical use.
tally administered in rats (3).
Intrahepatic Stem Cells
Hepatocyte growth factor (HGF) may also have a role in the treatment of liver diseases. In a model of hepatic Intrahepatic stem cells would be, in theory, the ideal fibrosis induced by bile duct ligation in mice, gene thercells for the treatment of liver diseases because of their apy with a plasmid containing HGF gene caused an imlineage commitment. However, difficulties in isolation provement in hepatic injury and reductions in fibrosis, and culture have limited their use to only few experiproduction of TGF-β, and in alterations of bile duct epimental studies. Oval cells are well-characterized intrahethelium basal membrane (137) . patic stem cells, with the potential of differentiation into Insulin-like growth factor (IGF-1) stimulates the prohepatocytes and cholangiocytes (96) . Wang and colduction of HGF and inhibits the production of TGF-β leagues investigated the regenerative potential of oval by hepatic stellate cells (108). The therapeutic potential cells in Fah −/− mice. Oval cells were isolated from livers of IGF-1 was tested in the model of CCl 4 -induced liver of wild-type mice and injected into the spleen of Fah −/− cirrhosis in rats (67) . In this study, a reduction in collamice. The injection of oval cells was more efficient than gen amounts and portal pressure were seen in cirrhotic treatment with mature hepatocytes (132) . In a model of animals treated with this factor. hepatic injury caused by partial hepatectomy associated with administration of monocrotaline, a drug that inhib-CLINICAL STUDIES IN CELL THERAPY its the proliferation of hepatocytes, wild-type animals re-
FOR LIVER DISEASES ceived transplantation of oval cells transfected with a
After the publications of studies with transplants of vector carrying α1-antitripsin and green fluorescent probone marrow mononuclear and mesenchymal cells in anitein genes (GFP) (115). It was observed the presence of mals with hepatic cirrhosis, some investigators evaluated hepatic cells expressing those markers in about 40-50% the potential of cell therapy in patients with hepatic cirrhoof the total parenchyma 18 weeks after transplantation. sis in phase I safety and feasibility studies. Therefore, most Growth Factors of the published data came from uncontrolled studies. Some studies have assessed the safety of using high A possible alternative to the transplantation of stem cells in liver diseases is the activation of resident stem doses of G-CSF to mobilize stem cells to the periphery in patients with advanced liver disease, as well as the cells or the recruitment of extrahepatic stem cells achieved through the administration of growth factors. efficacy of this protocol in providing adequate numbers of cells for further transplantation. Other studies have Granulocyte-colony stimulating factor (G-CSF) is a cytokine that mobilizes hematopoietic stem cells to the pe-used bone marrow aspiration and further purification of the cell populations of interest. At this moment, those riphery and a large clinical experience has been built due to its use in hematologic diseases. In addition to its have been total mononuclear cells, CD34 + cells, CD133 + cells, or mesenchymal stem cells. The types of protocol role in bone marrow stem cells recruitment, it is known that oval cells express G-CSF receptors and therefore a used are described in Table 3 . Gaia et al. evaluated the safety and feasibility of the direct action of this cytokine in the intrahepatic progenitors has been postulated (97) . An increased proliferation isolated mobilization of bone marrow mononuclear cells in eight patients with terminal stage hepatic cirrhosis, of intrahepatic progenitor cells was reported in patients with steato-hepatitis 7 days after G-CSF administration submitted to the application of G-CSF. The mobilization of CD34 + bone marrow cells was observed in all of the (117) . Furthermore, treatment with G-CSF led to a significantly increased oval cell reaction following partial patients after the application of G-CSF, which was well tolerated and free of adverse events. The Child-Pugh hepatoctomy and acetylaminofluorene administration in rats, in addition to migration of bone marrow progeni-score decreased two or more points in three patients, increased in one patient, while having no alterations (or tors to the liver (97) .
Treatment with G-CSF is also associated with im-decreased fewer than 2 points) in three patients. The MELD score decreased from an average pretreatment provement in liver injuries in some experimental studies. Quintana-Bustamante and colleagues demonstrated that value of 17.5 (variation of 11-20) to 14.5 (variation of 9-20) at the end of follow-up (37) . the administration of G-CSF in mice with liver injuries whether induced by CCl 4 or due to Fah deficiency im-Yannaki et al. included two patients with decompensated liver cirrhosis in the protocol of the study. The proved the generation of bone marrow-derived hepatocytes (100) . The administration of G-CSF in both acute patients were submitted to one or three rounds of G-CSF and, afterwards, the mobilized cells were collected and and chronic liver injuries induced by CCl 4 in mice promoted improvement in liver injuries by increased regen-infused via a peripheral vein. The procedure was well tolerated and the authors reported an improvement in eration and cell proliferation, correlating with the presence of hepatocytes derived from mobilized cells (140).
Child-Pugh and MELD scores after 12 months (139) . Two patients with cirrhosis Noncontrolled study; G-CSF in high doses associated with infusion of 139 CD34 + cells (obtained from peripheral blood) through the peripheral vein −2.3-4 × 10 6 /kg cells for each patient.
Eight patients with cirrhosis
Noncontrolled study; Mobilization of CD34 + cells with G-CSF. 37
Five patients with cirrhosis Noncontrolled study; Infusion of CD34 + cells obtained from peripheral 41 blood after mobilization with G-CSF; Infusion through the hepatic artery (n = 2) and portal vein (n = 3); Infusion of 1 × 10 6 to 2 × 10 8 cells/ patient Gordon et al. verified the safety and feasibility of au-of cell infusion. Three of the five patients presented improvement in serum bilirubin levels and four patients tologous bone marrow cells transplantation in five patients with chronic liver insufficiency. The authors stim-improved their albumin levels during the observation period of 60 days (41) . In a subsequent publication, the ulated the bone marrow with subcutaneous injections of G-CSF and used a selected population of adherent same authors reported the follow-up results of the five patients during a period of 12-18 months. All the pa-CD34 + cells mobilized to the peripheral blood. Five patients were included and submitted to all the study tients remained without complications or adverse events related to the procedure and the partial improvement of phases. The patients received 520 µg of G-CSF during 5 days and then were subjected to leukopheresis to ob-liver function lasted approximately 12 months (64) . A recently published study by Pai et al. evaluated the tain the CD34 + on day 5. Three patients received the CD34 + cells via portal vein injections and two received feasibility and safety of autologous transplantation of in vitro expanded CD34 + cells into nine patients suffering them via hepatic artery. No specific side effects were observed, except for light pain and discomfort at the site from alcoholic liver cirrhosis. To be included in the study, patients must have abstained from alcohol for at transplantation in patients with chronic liver disease (68) . Thirty patients that were on the liver transplant least 6 months. After G-CSF mobilization and leukapheresis, CD34 + cells were cultured and expanded fivefold waiting list joined the study and were randomly selected to receive either cell therapy with bone marrow mono-in medium supplemented with cytokines (IL-3, G-CSF, SCF, and GM-CSF) for 7 days, when they were har-nuclear cells (15 patients) or no intervention (15 patients). Autologous mononuclear cells were isolated vested and transplanted. Each patient received approximately 2 × 10 8 cells via hepatic artery. The procedure from bone marrow aspirates and then injected into the hepatic artery. The results showed that the Child-Pugh was well tolerated and the patients had significant decreases in serum bilirubin, seven of them showed an im-score improved within 90 days in the cell therapy group, compared to the control group (p = 0.017). The MELD provement in the Child-Pugh score, while five had an improvement in ascites on imaging (93) .
figure remained stable in the treated patients, while it increased in the control group during the treatment. The Terai et al. studied nine patients with advanced hepatic cirrhosis. The protocol included aspiration of 400 serum albumin levels improved in the treatment group, while remaining stable in the control group in the first ml of bone marrow from the iliac crest region, isolation of mononuclear cells, and infusion via peripheral vein. 90 days (p = 0.034). The serum bilirubin levels increased among the control group patients and decreased A significant improvement was observed in the average total protein serum levels, as well as albumin and the in the treatment group during the first 60 days. The effects that were observed did not remain after 90 days. Child-Pugh score during the follow-up period of 24 weeks. Five patients showed improvement of ascites. No
The study conclusions were that transplanting autologous CMN-MO cells via hepatic artery seems to im-specific side effects occurred, besides fever on the first day, after the cell infusion, in all the patients (125) .
prove liver function in patients with advanced cirrhosis, in the first 90 days (68).
Mohamadnejad et al. evaluated the safety and feasibility of infusing mesenchymal stem cells in four pa-
A study performed by am Esch et al. assessed the effects therapy with bone marrow autologous CD133 + tients with decompensated hepatic cirrhosis. After aspiration from the bone marrow, mesenchymal stem cells cells on hepatic regeneration after selective portal venous embolization in patients with malignant hepatic le-were cultivated and reinfused in the peripheral vein. The results demonstrated that no side effects occurred. The sions in preparation for extensive liver ressection. In this unrandomized study, authors compared a group of three MELD score of two patients decreased 3 and 4 points, respectively. The quality of life, evaluated using the SF-patients that were submitted to selective portal venous embolization alone with a group of three patients that 36 questionnaire, improved in the four patients (19). The same authors reported increased mortality and complica-received autologous CD133 + cells through infusion to nonoccluded hepatic branches after the procedure. The tions when patients with decompensated cirrhosis were submitted to the transplantation of mesenchymal stem group submitted to the stem cell infusion protocol improved the hepatic regeneration compared to the refer-cells using the hepatic artery as administration route and the study was prematurely stopped (80) . ence group, as demonstrated by increased daily growth rates and total liver volumes obtained by computed to-Our group carried out a safety and feasibility study, using cell therapy in patients with hepatic cirrhosis (69) . mography scans (4). This result was also reported in a subsequent work with a larger number of patients and a Ten patients with advanced chronic liver disease received intrahepatic artery infusions of mononuclear cells longer follow up (36). Summarizing the findings of clinical studies [re-collected by bone marrow aspiration. The patients received a 4-month follow-up. The adverse events were viewed in (49)], therapy with bone marrow cells is apparently safe and feasible, and was able to promote minimal, considering that only two patients complained of light pain at the site of the bone marrow tap. No other increased liver regeneration and improvement in functional liver parameters like serum albumin, bilirubin complication or specific side effects related to the procedure were observed. It was observed a reduction in total levels, correlating with improved Child-Pugh and MELD scores. However, most of the available data bilirubin levels 1 month (2.19 ± 0.9 mg/dl) and 4 months (2.10 ± 1.0 mg/dl) after the transplant of mono-came from nonrandomized studies with small numbers of patients. Further studies are necessary to define the nuclear cells, when compared to baseline levels (2.78 ± 1.2 mg/dl). The serum albumin levels 4 months after the role of cell therapy in patients with cirrhosis as well as the type of clinical profile of patients that would have infusion of CMN-MO (3.73 ± 0.5 g/dl) were higher than those at baseline (3.47 ± 0.5 g/dl).
the best response to the therapy. Another question that still needs to be resolved is which type of cell possesses After assessing security and feasibility, our group performed the first controlled, randomized pilot study to the best safety and efficacy to be used in clinical practice. evaluate the efficacy of autologous bone marrow cell 
